JP2017537881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537881A5 JP2017537881A5 JP2017520314A JP2017520314A JP2017537881A5 JP 2017537881 A5 JP2017537881 A5 JP 2017537881A5 JP 2017520314 A JP2017520314 A JP 2017520314A JP 2017520314 A JP2017520314 A JP 2017520314A JP 2017537881 A5 JP2017537881 A5 JP 2017537881A5
- Authority
- JP
- Japan
- Prior art keywords
- biodegradable carrier
- anticonvulsant
- composition
- poly
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001961 anticonvulsive agent Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 4
- 229940125681 anticonvulsant agent Drugs 0.000 claims description 3
- 230000001773 anti-convulsant effect Effects 0.000 claims 7
- 229960003965 antiepileptics Drugs 0.000 claims 7
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229940065514 poly(lactide) Drugs 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 238000002296 dynamic light scattering Methods 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000000454 anti-cipatory effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000001535 kindling effect Effects 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081162P | 2014-11-18 | 2014-11-18 | |
| US62/081,162 | 2014-11-18 | ||
| PCT/US2015/017112 WO2016081022A1 (en) | 2014-11-18 | 2015-02-23 | Compositions for treating acute, post-operative, or chronic pain and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537881A JP2017537881A (ja) | 2017-12-21 |
| JP2017537881A5 true JP2017537881A5 (https=) | 2018-03-29 |
Family
ID=55960737
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520314A Pending JP2017537881A (ja) | 2014-11-18 | 2015-02-23 | 急性、術後、または慢性疼痛を治療する組成物およびその使用方法 |
| JP2017526095A Pending JP2017533943A (ja) | 2014-11-18 | 2015-11-11 | 急性、術後、または慢性疼痛を治療する組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526095A Pending JP2017533943A (ja) | 2014-11-18 | 2015-11-11 | 急性、術後、または慢性疼痛を治療する組成物およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20160136179A1 (https=) |
| EP (2) | EP3220955A4 (https=) |
| JP (2) | JP2017537881A (https=) |
| CN (2) | CN107206097A (https=) |
| AU (2) | AU2015350554A1 (https=) |
| BR (2) | BR112017010430A2 (https=) |
| CA (2) | CA2967287A1 (https=) |
| IL (2) | IL251880A0 (https=) |
| MX (2) | MX2017006388A (https=) |
| WO (3) | WO2016081022A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170239183A1 (en) * | 2016-02-23 | 2017-08-24 | PixarBio Corporation | COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME |
| CN106902095B (zh) * | 2017-03-08 | 2021-11-05 | 东北林业大学 | 一种集化疗与免疫疗法为一体的载黄芩苷纳米制剂及其制备方法 |
| US20180338929A1 (en) * | 2017-05-23 | 2018-11-29 | Soon Kap Hahn | Method and Compounds for Treating Peripheral Neuropathy |
| US11571429B2 (en) * | 2017-05-23 | 2023-02-07 | Upexmed Co. Ltd. | Method and compounds for treating peripheral neuropathy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166800A (en) * | 1977-08-25 | 1979-09-04 | Sandoz, Inc. | Processes for preparation of microspheres |
| IL86211A (en) * | 1987-05-04 | 1992-03-29 | Ciba Geigy Ag | Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation |
| US5948384A (en) * | 1990-09-14 | 1999-09-07 | Syngenix Limited | Particulate agents |
| US20030056896A1 (en) * | 1995-05-12 | 2003-03-27 | Frank Jao | Effective therapy for epilepsies |
| MX9700850A (es) * | 1995-06-09 | 1997-09-30 | Euro Celtique Sa | Formulaciones y metodos para proporcionar anestesia local prolongada. |
| EP1575562B1 (en) * | 2002-11-26 | 2016-10-05 | Seacoast Neurosciene, Inc. | Buoyant polymer particles delivering therapeutic agents |
| EP1781257B1 (en) * | 2004-08-13 | 2018-12-19 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| JP4954085B2 (ja) * | 2004-12-06 | 2012-06-13 | メディシノバ， インコーポレイテッド | 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト |
| US20100204178A1 (en) * | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| JP2009533455A (ja) * | 2006-04-12 | 2009-09-17 | マサチューセッツ インスティテュート オブ テクノロジー | 癒着を阻害するための組成物および方法 |
| US20070253994A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain |
| JP5630998B2 (ja) * | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | 機能的粒子のためのポリマー |
| WO2007137117A2 (en) * | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| RU2522493C2 (ru) * | 2008-03-04 | 2014-07-20 | Пфайзер Лимитед | Способы лечения хронической боли |
| RU2508093C2 (ru) * | 2008-07-01 | 2014-02-27 | Нитто Денко Корпорейшн | Фармацевтическая композиция, содержащая микрочастицы с поверхностным покрытием |
| CN102348468B (zh) * | 2009-07-31 | 2014-11-05 | 西安力邦医药科技有限责任公司 | 微球药物载体、其制备方法、组合物及应用 |
| AU2010278601A1 (en) * | 2009-07-31 | 2012-02-23 | Xi'an Libang Medical Technology Co., Ltd | Nanosphere or microsphere drug carrier, preparation method, composition and use thereof |
| US9549901B2 (en) * | 2010-09-03 | 2017-01-24 | The Brigham And Women's Hospital, Inc. | Lipid-polymer hybrid particles |
| US9301946B2 (en) * | 2010-12-03 | 2016-04-05 | Warsaw Orthopedic, Inc. | Clonidine and GABA compounds in a biodegradable polymer carrier |
| ES2683902T3 (es) * | 2011-06-14 | 2018-09-28 | Hale Biopharma Ventures, Llc | Administración de benzodiacepina |
| BR112014006596A2 (pt) * | 2011-09-21 | 2017-03-28 | Yissum Res Dev Co | nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas |
| AU2013352141B2 (en) * | 2012-11-30 | 2018-04-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| CN103610664B (zh) * | 2013-12-11 | 2015-09-16 | 中国药科大学 | 一种制备卡马西平聚乳酸-羟基乙酸共聚物微胶囊的方法 |
-
2015
- 2015-02-23 JP JP2017520314A patent/JP2017537881A/ja active Pending
- 2015-02-23 US US14/628,563 patent/US20160136179A1/en not_active Abandoned
- 2015-02-23 AU AU2015350554A patent/AU2015350554A1/en not_active Abandoned
- 2015-02-23 CN CN201580062137.2A patent/CN107206097A/zh active Pending
- 2015-02-23 BR BR112017010430A patent/BR112017010430A2/pt not_active IP Right Cessation
- 2015-02-23 WO PCT/US2015/017112 patent/WO2016081022A1/en not_active Ceased
- 2015-02-23 EP EP15861856.1A patent/EP3220955A4/en not_active Withdrawn
- 2015-02-23 CA CA2967287A patent/CA2967287A1/en not_active Abandoned
- 2015-02-23 MX MX2017006388A patent/MX2017006388A/es unknown
- 2015-11-11 MX MX2017006422A patent/MX2017006422A/es unknown
- 2015-11-11 JP JP2017526095A patent/JP2017533943A/ja active Pending
- 2015-11-11 CA CA2967335A patent/CA2967335A1/en not_active Abandoned
- 2015-11-11 EP EP15861866.0A patent/EP3220917A4/en not_active Withdrawn
- 2015-11-11 WO PCT/US2015/060093 patent/WO2016081236A1/en not_active Ceased
- 2015-11-11 BR BR112017010428A patent/BR112017010428A2/pt not_active Application Discontinuation
- 2015-11-11 CN CN201580062194.0A patent/CN107405351A/zh active Pending
- 2015-11-11 AU AU2015350347A patent/AU2015350347A1/en not_active Abandoned
- 2015-11-17 WO PCT/US2015/061066 patent/WO2016081445A1/en not_active Ceased
-
2016
- 2016-07-13 US US15/208,923 patent/US20160317446A1/en not_active Abandoned
-
2017
- 2017-04-24 IL IL251880A patent/IL251880A0/en unknown
- 2017-04-24 IL IL251881A patent/IL251881A0/en unknown
- 2017-04-25 US US15/496,827 patent/US20170224621A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jonassen et al. | Stability of chitosan nanoparticles cross-linked with tripolyphosphate | |
| Biswas et al. | Chitosan and its derivatives as nanocarriers for drug delivery | |
| Suhail et al. | Nanogels as drug-delivery systems: A comprehensive overview | |
| Stevanović et al. | A review of recent developments in biopolymer nano-based drug delivery systems with antioxidative properties: Insights into the last five years | |
| Mashabela et al. | A comprehensive review of cross-linked gels as vehicles for drug delivery to treat central nervous system disorders | |
| Zhang et al. | Formation and stability of core–shell nanofibers by electrospinning of gel-like corn oil-in-water emulsions stabilized by gelatin | |
| Turk et al. | Formulation and optimization of nonionic surfactants emulsified nimesulide-loaded PLGA-based nanoparticles by design of experiments | |
| Hu et al. | Optimization of fabrication parameters to produce chitosan− tripolyphosphate nanoparticles for delivery of tea catechins | |
| Tuomela et al. | Stabilizing agents for drug nanocrystals: effect on bioavailability | |
| Pillai et al. | Folic acid conjugated cross-linked acrylic polymer (FA-CLAP) hydrogel for site specific delivery of hydrophobic drugs to cancer cells | |
| Frasco et al. | Transferrin surface‐modified PLGA nanoparticles‐mediated delivery of a proteasome inhibitor to human pancreatic cancer cells | |
| O’Toole et al. | Curcumin encapsulation in submicrometer spray-dried chitosan/tween 20 particles | |
| Radu et al. | Poly (3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer | |
| EP4393549A3 (en) | Compositions for the delivery of trna as nanoparticles and methods of use therewith | |
| Andorko et al. | Impact of molecular weight on the intrinsic immunogenic activity of poly (beta amino esters) | |
| Park et al. | Quality by design: screening of critical variables and formulation optimization of Eudragit E nanoparticles containing dutasteride | |
| McCarron et al. | Celecoxib-loaded poly (D, L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure | |
| Romero et al. | Surface Engineered Poly (lactide-co-glycolide) Nanoparticles for Intracellular Delivery: Uptake and Cytotoxicity A Confocal Raman Microscopic Study | |
| JP2017537881A5 (https=) | ||
| Zewail | Folic acid decorated chitosan-coated solid lipid nanoparticles for the oral treatment of rheumatoid arthritis | |
| Kastantin et al. | Thermodynamic and kinetic stability of DSPE-PEG (2000) micelles in the presence of bovine serum albumin | |
| Jani et al. | Formulation of polymeric nanoparticles of antidepressant drug for intranasal delivery | |
| Thakker et al. | Inter-polymer complex microspheres of chitosan and cellulose acetate phthalate for oral delivery of 5-fluorouracil | |
| Liu et al. | Polymeric biomaterials: Advanced drug delivery systems in osteoarthritis treatment | |
| Akbal et al. | Comparison of protein-and polysaccharide-based nanoparticles for cancer therapy: Synthesis, characterization, drug release, and interaction with a breast cancer cell line |